The Impact of Different Hepatitis B Virus Serological Statuses on the Safety of Different Chemotherapy Regimens in Female Breast Cancer Patients: A Within-Subject Longitudinal Study

Background: Breast cancer patients with hepatitis B virus (HBV) infection or past HBV infection face heightened risks of chemotherapy-induced hepatotoxicity and HBV reactivation (HBVr). This study aims to evaluate the impact of different HBV serological statuses on the safety of chemotherapy regimen...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancers Ročník 17; číslo 21; s. 3574
Hlavní autoři:	Li, Zhao-Xing, Liu, Dong-Li, Hu, Lei, Peng, Bai-Qing, Qu, Xiu-Quan, Mu, Li-Yuan, Cheng, Xiao-Chun, Qiu, Pu, Huang, Yu-Xuan, Li, Xi-Rui, Kong, Ling-Quan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland MDPI AG 05.11.2025
Témata:	Analysis Antiviral agents Breast cancer Cancer Cancer patients Cancer therapies Care and treatment Chemotherapy Disease prevention Females Health aspects Hepatitis B Hepatitis B surface antigen Hepatitis B virus Hepatotoxicity Infection Infections Leukocytes Liver Longitudinal studies Oncology, Experimental Paclitaxel Safety and security measures Serology Viruses Women Womens health China breast cancer chemotherapy safety HBV reactivation hepatitis B virus hepatotoxicity
ISSN:	2072-6694, 2072-6694
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!